Low-molecular-weight heparins for the treatment of acute coronary syndrome and venous thromboembolism in patients with chronic renal insufficiency

Thrombosis Research

Volumn 118, Issue 3, 2006, Pages 409-416

  Lim, Wendy ^a   Al Saleh, Khalid ^a   Douketis, James D ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Acute coronary syndrome; Chronic renal insufficiency; Low molecular weight heparin; Venous thromboembolism

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; DALTEPARIN; DILTIAZEM; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; GLYCERYL TRINITRATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; RAMIPRIL; TICLOPIDINE; TINZAPARIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; TREATMENT WITHDRAWAL; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ANGINA, UNSTABLE; ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY DISEASES; MYOCARDIAL INFARCTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; SYNDROME; VENOUS THROMBOSIS;

EID: 33746800118     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.03.028     Document Type: Article

References (65)

1. Wharton S., Al Malki H., Crowther M.A., Gangi A., Ingram A.J., Kohli S., et al. Cardiac and vascular disease and medication use in patients referred to a nephrologist with chronic renal insufficiency. Canadian Society of Nephrology (2003 (May)) [St. John's, Nfld (abstract)]
2. Levin A., Djurdjiev O., Barrett E., Burgess E., Carlisle E., Ethier J., et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 38 (2001) 1398-1407
3. Gerlach A.T., Pickworth K.K., Seth S.K., Tanna S.B., and Barnes J.F. Enoxaparin and bleeding complications in patients with and without renal insufficiency. Pharmacotherapy 20 (2000) 771-775
4. Macie C., Forbes L., Foster G.A., and Douketis J.D. Enoxaparin use in patients with an acute coronary syndrome. Prescribing practices and bleeding risk. Chest 125 (2004) 1616-1621
5. Becker R.C., Spencer F.A., Gibson M., Rush J.E., Sanderink G., Murphy S.A., et al. Influence of patient characteristics and renal function and factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143 (2002) 753-759
6. Buller H.R., Davidson B.L., Decousus H., Gallus A., Gent M., Piovella F., et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 (2003) 1695-1702
7. Heit J.A. Venous thromboembolism epidemiology: implications for prevention and management. Semin Thromb Haemost 28 suppl 2 (2002) 3-13
8. Boersma E., Mercado N., Poldermans D., Gardien M., Vas J., and Simoons M.L. Acute myocardial infarction. Lancet 361 (2003) 847-858
9. Duncan L., Heathcote J., Djurdjev O., and Levin A. Screening for renal disease using serum creatinine: who are we missing?. Nephrol Dial Transplant 16 (2001) 1042-1046
10. Epstein M. Aging and the kidneys. J Am Soc Nephrol 7 (1996) 1106-1122
11. Clase C.M., Garg A.X., and Kiberd B. Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration. J Am Soc Nephrol 13 (2002) 2812-2816
12. Swedko P.J., Clark H.D., Paramsouthy K., and Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 163 (2003) 356-360
13. K/DOQI clinical practice guidelines for chronic renal disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39 suppl 2 (2002) S1-S46
14. Boneu B., and de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Haemost 27 (2001) 519-522
15. Cohen M., Demers C., Gurfinkel E.P., Turpie A.G., Fromell G.J., Goodman S., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 337 (1997) 447-452
16. Duplaga B.A., Rivers C.W., and Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 21 (2001) 218-234
17. Dunn A.S., and Coller B. Out patient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med 106 (1999) 660-669
18. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 188S-203S
19. Schulman S. Unresolved issues in anticoagulant therapy. J Thromb Haemost 1 (2003) 1464-1470
20. Nagge J., Crowther M., and Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin?. Arch Intern Med 162 (2002) 2605-2609
21. Hory B., Claudet M.H., Magnette J., Bechtel P., and Bayrou B. Pharmacodynamics of a very low molecular weight heparin in chronic renal failure. Thromb Res 63 (1991) 311-317
22. Cadroy Y., Pourrat Y., Baladre M.F., Saivin S., Houin G., Montastruc J.L., et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 63 (1991) 385-390
23. R) in various stages of chronic renal failure. Nephron 59 (1991) 543-545
24. Mismetti P., Laporte-Simitsidis S., Navarro C., Sie P., D'Azemar P., Necciari J., et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low-molecular weight heparin (nadroparin). Thrombo Haemost 79 (1998) 1162-1165
25. R) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 84 (2000) 800-804
26. Harrington R.A., Becker R.C., Ezekowitz M., Meade T.W., O'Connor C.M., Vorscheimer D.A., et al. Antithrombotic therapy for coronary artery disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 513S-548S
27. Braunwald E., Antman E.M., Beasley J.W., Califf R.M., Cheitlin M.D., Hochman J.S., et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). ACC/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 106 (2002) 1893-1900
28. Bertrand M.E., Simoons M.L., Fox K.A., Wallentin L.C., Hamm C.W., McFadden E., et al., Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 23 (2002) 1809-1840
29. Buller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., and Raskob G.E. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 401S-428S
30. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 337 (1997) 688-698
31. Douketis J.D. Treatment of deep vein thrombosis: what factors determine appropriate treatment?. Can Fam Physician 51 (2005 (Feb)) 217-223
32. Wells P.S. Outpatient treatment of patients with deep vein thrombosis and pulmonary embolism. Curr Opin Pulm Med 7 (2001) 360-364
33. Brosa M., Rubio-Terres C., Farr I., Nadipelli V., and Froufe J. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome. Pharmacoeconomics 20 (2002) 979-987
34. O'Brien B.J., Willan A., Blackhouse G., Goeree R., Cohen M., and Goodman S. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?. Am Heart J 139 (2000) 423-429
35. Rodger M., Brederson Wells P.S., Beck J., Kearns B., and Huebsch L.B. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ 159 (1998) 931-938
36. Anderson D.R., and O'Brien B.J. Cost-effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism. Pharmacoeconomics 12 (1997) 17-19
37. Chong B. Heparin induced thrombocytopenia. J Thromb Haemost 1 (2003) 1471-1478
38. Antman E.M., McCabe C.H., Gurfinkel E.P., Turpie A.G., Bernink P.J., Salein D., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial. Circulation 100 (1999) 1593-1601
39. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacodynamics and metabolism in humans. Haemostasis 26 Suppl 2 (1996) 24-38
40. Cornelli U., and Fareed J. Human pharmacodynamics of low molecular weight heparins. Semin Thromb Hemost 25 Suppl 3 (1999) 57-61
41. Pedersen P.C., Ostergaard P.B., Hedner U., Bergqvist D., and Matzsch T. Pharmacodynamics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb Res 61 (1991) 477-487
42. Barrett J.S., Hainer J.W., Kornhauser D.M., Gaskill J.L., Hue T.A., Sprogel P., et al. Anticoagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers. Thromb Res 101 (2001) 243-254
43. Pautas E., Gouin I., Bellot O., Andreux J.P., and Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Safety 25 (2002) 725-733
44. Hull R.D., Raskob G.E., Pineo G.F., Green D., Trowbridge A.A., Elliott C.G., et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 326 (1992) 975-982
45. Barrett J.S., Giliansky E., Hull R.D., Planes A., Pentikis H., Hainer J.W., et al. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 39 (2001) 431-436
46. Collignon F., Frydman A., Caplain H., Ozoux M.L., Le Roux Y., Bouthier J., et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 73 (1995) 630-640
47. Dolovich L.R., Ginsberg J.S., Douketis J.D., Holbrook A.M., and Cheah G. A meta-analysis comparing low molecular weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 160 (2000) 181-189
48. Lee A.Y.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
49. Douketis J.D., Johnson J.A., and Turpie A.G. Low-molecular-weight heparin as bridging anticoagulation in patients who require temporary interruption of warfarin for an elective surgical or invasive procedure: assessment of a standardized peri-procedural anticoagulation regimen. Arch Intern Med 169 (2004) 1319-1326
50. Lim W., Cook D.J., and Crowther M.A. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 15 (2004) 3192-3206
51. Polkinghorne K.R., McMahon L.P., and Becker G.J. Pharmacodynamic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 40 5 (2002) 990-995
52. Reeves J.H., Cumming A.R., Gallagher L., O'Brien J.L., and Santamaria J.D. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 27 10 (1999) 2224-2228
53. Ljungberg B., Jacobson S.H., Lins L.E., and Pejler G. Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane. Clin Nephrol 38 2 (1992) 97-100
54. Merli G., Spiro T.E., Olsson C.G., Abildgaard U., Davidson B.L., Eldor A., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for the treatment of venous thromboembolic disease. Ann Intern Med 134 (2001) 191-202
55. Marketing Reports (2002), Aventis Pharmaceuticals, Laval, PQ, Canada
56. Busby L.T., Weyman A., and Rodgers G.M. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol 67 (2001) 54-56
57. Antonelli D., Fares II L., and Anene C. Enoxaparin associated with huge abdominal wall hematomas: a report of two cases. Am Surg 66 (2000) 797-800
58. Farooq V., Hegarty J., Chandrasekar T., Lamerton E.H., Mitra S., Houghton J.B., et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 43 (2004) 531-537
59. Spinler S.A., Inverso S.M., Cohen M., Goodman S.G., Stringer K.A., and Antman E.M. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 146 (2003) 33-41
60. Boneau B., Necciari J., Cariou R., Sie P., Gabaig A.M., Kieffer G., et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org 31540) with high affinity to antithrombin III in man. Thromb Haemost 74 (1995) 1468-1473
61. Turpie A.G., Bauer K.A., Eriksson B.I., and Lasses M.R. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162 (2002) 1833-1840
62. Buller H.R., Davidson B.L., Decousus H., Gallus A., Gent M., Piovella F., et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140 (2004) 867-873
63. van Amsterdam R.G., Vogel G.M., Visser A., Kop W.J., Buiting M.T., and Meuleman D.G. Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times. Arterioscler Thromb Vasc Biol 15 (1995) 495-503
64. Herbert J.M., Herault J.P., Berant A., van Amsterdam R.G., Lormeau J.C., Petitou M., et al. Biochemical and pharmacologic properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 91 (1998) 4197-4220
65. Crowther M.A., Berry L.R., Monagle P.T., and Chan A.K.C. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 116 (2002) 178-186